| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.DRUDIS.2010.06.006 |
| P698 | PubMed publication ID | 20601095 |
| P2093 | author name string | David B Jackson | |
| Alejandro Merino | |||
| Dolores J Cahill | |||
| Agnieszka K Bronowska | |||
| P2860 | cites work | DrugBank: a knowledgebase for drugs, drug actions and drug targets | Q24650300 |
| DrugBank and its relevance to pharmacogenomics | Q44950782 | ||
| P433 | issue | 17-18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 749-756 | |
| P577 | publication date | 2010-06-18 | |
| P1433 | published in | Drug Discovery Today | Q3040085 |
| P1476 | title | Drug profiling: knowing where it hits | |
| P478 | volume | 15 |
| Q90296947 | A Method for Rapid Screening of Anilide-Containing AMPK Modulators Based on Computational Docking and Biological Validation |
| Q51159788 | A knowledge-based halogen bonding scoring function for predicting protein-ligand interactions. |
| Q41812083 | A new fingerprint to predict nonribosomal peptides activity. |
| Q40957448 | A quantum mechanics-based halogen bonding scoring function for protein-ligand interactions |
| Q33935909 | An active role for machine learning in drug development |
| Q35071339 | Balancing novelty with confined chemical space in modern drug discovery |
| Q90504580 | Computational design of substrate selective inhibition |
| Q87202121 | Deducing the mechanism of action of compounds identified in phenotypic screens by integrating their multiparametric profiles with a reference genetic screen |
| Q36088280 | Differential Virtual Screening (DVS) with Active and Inactive Molecular Models for Finding and Profiling GPCR Modulators: Case of the CCK1 Receptor |
| Q91806664 | Does in vitro potency predict clinical efficacious concentrations? |
| Q26748728 | Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders |
| Q36578017 | Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys |
| Q35177638 | Efficient discovery of responses of proteins to compounds using active learning |
| Q28537673 | Efficient modeling and active learning discovery of biological responses |
| Q38201052 | Exploring compound promiscuity patterns and multi-target activity spaces |
| Q28539182 | Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma |
| Q45961548 | Gaussian interaction profile kernels for predicting drug-target interaction. |
| Q30574444 | How promiscuous are pharmaceutically relevant compounds? A data-driven assessment |
| Q46311028 | Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1. |
| Q30372351 | Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders |
| Q38100299 | PARP inhibitors: polypharmacology versus selective inhibition |
| Q39499852 | Plugging the explicit σ-holes in molecular docking |
| Q49991176 | Safety evaluation of a triazine compound nitromezuril by assessing bacterial reverse mutation, sperm abnormalities, micronucleus and chromosomal aberration. |
| Q27144242 | Shifting from the single to the multitarget paradigm in drug discovery |
| Q34061894 | The interprotein scoring noises in glide docking scores. |
| Q28390743 | The new toxicology of sophisticated materials: nanotoxicology and beyond |
| Q36280059 | The scoring bias in reverse docking and the score normalization strategy to improve success rate of target fishing. |
| Q97678692 | Translation of in vitro cannabinoid 1 receptor agonist activity to in vivo pharmacodynamic endpoints |
| Q34680149 | What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data |
Search more.